Collegium Pharmaceutical, Inc.

NasdaqGS:COLL 주식 보고서

시가총액: US$1.2b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Collegium Pharmaceutical 미래 성장

Future 기준 확인 2/6

Collegium Pharmaceutical은 연간 수입과 매출이 각각 22.3%와 2.9% 증가할 것으로 예상되고 EPS는 연간 16.5%만큼 증가할 것으로 예상됩니다.

주요 정보

18.8%

수익 성장률

12.5%

EPS 성장률

Pharmaceuticals 수익 성장23.6%
매출 성장률2.2%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트04 Sep 2024

최근 미래 성장 업데이트

Recent updates

Collegium Pharmaceutical: Diversifying And Growing

Aug 09

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Jul 24
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Jun 05
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

May 13

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10
It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24
These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05
There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12
Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Aug 09
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Mar 10
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Oct 18
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Jun 24
Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical: Oversold And Cheap

Jun 12

Collegium Pharmaceutical: Thoughts After Another Strategic Move

Feb 20

수익 및 매출 성장 예측

NasdaqGS:COLL - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20267421352863674
12/31/20257301333283544
12/31/20246341062843493
6/30/2024577100276277N/A
3/31/202456793308309N/A
12/31/202356748274275N/A
9/30/20235479266268N/A
6/30/2023537-11235236N/A
3/31/2023525-29176177N/A
12/31/2022464-25123124N/A
9/30/2022362-439394N/A
6/30/2022314-356769N/A
3/31/2022273435658N/A
12/31/202127772102104N/A
9/30/20213261048790N/A
6/30/2021326107102107N/A
3/31/202132142115121N/A
12/31/202031027-28094N/A
9/30/202030818-28687N/A
6/30/20203020-31359N/A
3/31/2020299-13-34130N/A
12/31/2019297-232128N/A
9/30/2019296-114754N/A
6/30/2019293-228190N/A
3/31/2019291-30123131N/A
12/31/2018280-39145169N/A
9/30/2018218-6691114N/A
6/30/2018160-623959N/A
3/31/201890-70N/A-14N/A
12/31/201728-75N/A-67N/A
9/30/201719-85N/A-77N/A
6/30/20177-98N/A-84N/A
3/31/20174-102N/A-87N/A
12/31/20162-94N/A-75N/A
9/30/20160-76N/A-61N/A
6/30/2016N/A-59N/A-48N/A
3/31/2016N/A-40N/A-31N/A
12/31/2015N/A-20N/A-22N/A
9/30/2015N/A-15N/A-20N/A
6/30/2015N/A-13N/A-18N/A
3/31/2015N/A-12N/A-16N/A
12/31/2014N/A-21N/A-18N/A

애널리스트 미래 성장 예측

수입 대 저축률: COLL 의 연간 예상 수익 증가율( 15.9% )이 saving rate( 2.4% 보다 높습니다. ).

수익 vs 시장: COLL 의 연간 수익( 15.9% ) US 시장( 14.9% 보다 빠르게 성장할 것으로 예상됩니다. 14.9% 연간).

고성장 수익: COLL 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: COLL 의 수익(연간 0.3% ) US 시장( 8.6% 보다 느리게 성장할 것으로 예상됩니다. 8.6% 연간).

고성장 수익: COLL 의 수익(연간 0.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: COLL 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견